Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amarin Corp Ads (AMRN)

Amarin Corp Ads (AMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,518,956
  • Shares Outstanding, K 357,214
  • Annual Sales, $ 229,210 K
  • Annual Income, $ -116,450 K
  • 60-Month Beta 1.09
  • Price/Sales 23.72
  • Price/Cash Flow N/A
  • Price/Book 39.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.04
  • Number of Estimates 4
  • High Estimate -0.01
  • Low Estimate -0.05
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.87 +14.35%
on 10/02/19
17.55 -9.65%
on 09/17/19
-0.85 (-5.09%)
since 09/13/19
3-Month
13.76 +15.26%
on 08/12/19
21.94 -27.71%
on 07/16/19
-6.01 (-27.48%)
since 07/15/19
52-Week
11.78 +34.63%
on 12/24/18
23.91 -33.67%
on 07/05/19
-3.43 (-17.78%)
since 10/15/18

Most Recent Stories

More News
Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman

Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019.

EVFM : 4.98 (-1.19%)
AMRN : 15.86 (+2.65%)
GWPH : 120.33 (+3.55%)
PRGO : 53.81 (+1.43%)
AGN : 170.16 (+0.72%)
Amarin to Participate in the Cantor Global Healthcare Conference

Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's...

AMRN : 15.86 (+2.65%)
Biotech Brief: Latest Electrophysiology Devices Vastly Improving Diagnosis and Treatment of Cardiovascular Diseases

According to a recent market research report published by Grand View Research, a consulting and advisory service firm that provides comprehensive, research-based views crucial for building business intelligence...

BSGM : 7.28 (+4.00%)
AMRN : 15.86 (+2.65%)
BHVN : 44.63 (+3.50%)
AIMT : 25.00 (+3.24%)
New 2019 Updates to the European Society of Cardiology's and European Atherosclerosis Society's Guidelines for the Management of Dyslipidaemias Incorporate Findings from the REDUCE-IT(TM) Cardiovascular Outcomes Study

Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that the European Society of Cardiology (ESC) and the European Atherosclerosis...

AMRN : 15.86 (+2.65%)
Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference

Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's...

AMRN : 15.86 (+2.65%)
Amarin to Participate in a Fireside Chat at Citi's 14th Annual Biotech Conference

Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's...

AMRN : 15.86 (+2.65%)
Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More

Key highlights of the past week include collaborations, and other regulatory and pipeline news.

AMGN : 204.66 (+0.87%)
ALNY : 80.85 (+2.16%)
GILD : 65.30 (+1.22%)
REGN : 303.82 (-0.53%)
AMRN : 15.86 (+2.65%)
Non-Invasive Cellulite Treatments and Devices Dominating Billion Dollar Market

People with cellulite are not as happy as those without cellulite. That may seem to be self-evident, but now it is supported by studies. One such report, a study published by Surgical and Cosmetic Dermatology,...

SOLY : 12.86 (+2.47%)
DCPH : 34.43 (+3.83%)
AMRN : 15.86 (+2.65%)
LLY : 109.70 (+1.67%)
GILD : 65.30 (+1.22%)
Amarin (AMRN) Alert: Johnson Fistel Launches Investigation into Amarin Corporation plc; Investors Encouraged to Contact Firm

Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Amarin Corporation plc ("Amarin") (NASDAQ: AMRN) for violations of federal securities laws.

AMRN : 15.86 (+2.65%)
Amarin (AMRN) Beats Earnings & Beats Revenues in Q2

Amarin beats estimates for both earnings and revenues in the second quarter of 2019. Shares up.

AMRN : 15.86 (+2.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade AMRN with:

Business Summary

Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies.

See More

Key Turning Points

2nd Resistance Point 16.42
1st Resistance Point 16.14
Last Price 15.86
1st Support Level 15.46
2nd Support Level 15.06

See More

52-Week High 23.91
Fibonacci 61.8% 19.28
Fibonacci 50% 17.84
Fibonacci 38.2% 16.41
Last Price 15.86
52-Week Low 11.78

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar